Citations

Clear

4510 citation(s) found for "Scott, C".

Macrophage peroxisomes guide alveolar regeneration and limit SARS-CoV-2 tissue sequelae
Wei, Xiaoqin , Qian, Wei , Narasimhan, Harish , Chan, T. K., Liu, Xue , Arish, Mohd , Young, Scott , Li, Chaofan , Cheon, In Su , Yu, Qing , Santos, Gislane de Almeida , Yeatts, Eric V., Spear, Olivia J., Yi, Mou, Hahn, Young S. , Kaplan, Mark H. , Sperling, Anne I. , Shim, Yun M. , Vassallo, Robert , Chen, Peter , Roden, Anja C. , Que, Jianwen , Chan, Ting , Young, Samuel , de Almeida Santos, Gislane , Zhao, Xiao-Yu , Yeatts, Eric V , Parimon, Tanyalak , Fang, Yinshan , Hahn, Young S , Bullock, Timothy N J , Somerville, Lindsay A , Kaplan, Mark H , Sperling, Anne I , Shim, Yun Michael , Vassallo, Robert , Chen, Peter , Ewald, Sarah E , Roden, Anja C , Que, Jianwen , Jiang, Dianhua , Sun, Jie , Li, Chaofan , Yi, Megan, Somerville, Lindsay , Sun, Jie

Mayo Clinic

Science | March 6, 2025 | Volume: 387 | Issue: 6738 | Pages: No page available

10.1126/science.adq2509 | PMID 40048515 Get It

Peroxisomes are vital but often overlooked metabolic organelles. We found that excessive interferon signaling remodeled macrophage peroxisomes. This loss of peroxisomes impaired inflammation resolution and lung repair during severe respiratory viral infections. Peroxisomes were found to modulate lipid metabolism and mitochondrial health in a macrophage type-specific manner and enhanced alveolar macrophage-mediated tissue repair and alveolar regeneration after viral infection. Peroxisomes also prevented excessive macrophage inflammasome activation and IL-1β release, limiting accumulation of KRT8 high dysplastic epithelial progenitors following viral injury. Pharmacologically enhancing peroxisome biogenesis mitigated both acute symptoms and post-acute sequelae of COVID-19 (PASC) in animal models. Thus, macrophage peroxisome dysfunction contributes to chronic lung pathology and fibrosis after severe acute respiratory syndrome coronavirus 2 infection.
Association of Program Directors for Colon and Rectal Surgery: First 4 Decades
Kelley, Scott R. , Kelley, Scott R

Mayo Clinic

Diseases of the Colon & Rectum | March 5, 2025 | Volume: 68 | Issue: 6 | Pages: 675-681

10.1097/dcr.0000000000003260 | PMID 40044399 Get It

The Effect of Preoperative Tamsulosin on Pediatric Ureteroscopic Access: A Multi-Institutional Experience
Meyer, Kayla M., Asantey, Kwesi , Jadcherla, Aditya, Kostman, Tori, Ostergar, Adam , Traxel, Erica , Paradis, Alethea, Vetter, Joel , Davis, Erik S. , McGee, Lauren M. , Kraft, Kate H. , Ellison, Jonathan Scott , Storm, Douglas W. , Wendt, Linder , Eyck, Patrick Ten

Mayo Clinic

Urology Practice | March 5, 2025 | Volume: 12 | Issue: 4 | Pages: 408-414

10.1097/upj.0000000000000793 | PMID 40042500 Get It

Germline–Somatic Interactions in BRCA-Associated Cancers: Unique Molecular Profiles and Clinical Outcomes Linking ATM to TP53 Synthetic Essentiality
Arafa, Ali T., Yadav, Siddhartha , Marshall, Catherine H. , Mauer, Elizabeth , Huang, Minxuan , Yilma, Binyam , Pol, Ymke van der , Fragkogianni, Stamatina , Teslow, Emily A. , Kellen, Samuel , Boytim, Ella , Luo, Christine , Ludwig, Megan , Jayaraj, Arockia, Armstrong, Deborah K. , Isaacs, William B. , Nguyen, Hai Dang , Huang, R. Stephanie , Dehm, Scott M. , Hwang, Justin H. , Arafa, Ali T. , Arafa, Ali , van der Pol, Ymke , Zhang, Weijie , Jayaraj, Arockia , Armstrong, Deborah K , Isaacs, William B , Drake, Justin M , Nguyen, Hai Dang , Huang, R Stephanie , Chao, Calvin Y. , Lou, Emil , Dehm, Scott M , Couch, Fergus J. , Hwang, Justin H , Antonarakis, Emmanuel S , Mauer, Elizabeth , Yadav, Siddhartha , Marshall, Catherine H , Teslow, Emily A , Fragkogianni, Stamatina , Lou, Emil , Couch, Fergus J. , Antonarakis, Emmanuel S.

Mayo Clinic

Clinical Cancer Research | February 28, 2025 | Volume: 31 | Issue: 9 | Pages: 1730-1745

10.1158/1078-0432.ccr-24-2058 | PMID 40019487 Get It

Abstract Purpose: Germline alterations in homologous recombination repair (gHRR) genes affect the pathogenesis, treatment options, and survival of patients with cancer. However, distinct gHRR gene alterations may differentially affect treatment response and oncogenic signaling. In this study, we interrogated genomic and transcriptomic data and assessed clinical outcomes of patients with gHRR mutations across four BRCA-associated cancers (breast, ovarian, pancreatic, and prostate cancers) to identify therapeutic vulnerabilities. Experimental Design: We assessed 24,309 patients undergoing matched tumor/normal next-generation DNA and RNA sequencing. Annotated gHRR gene variants [germline BRCA1, germline BRCA2, germline PALB2, germline ATM (gATM), and germline CHEK2] were analyzed. HRs were used to assess survival outcomes comparing germline versus sporadic groups. Somatic alterations and their frequencies were compared across gHRR-altered groups. Differential gene expression and gene set enrichment analysis were used to compare transcriptomic profiles. Results: Somatic TP53 mutations were depleted in gATM carriers (P < 0.05) across all four BRCA-associated cancers by up to 2.5-fold. Tumors with germline BRCA1/2 mutations were associated with improved survival in patients with ovarian cancer and had consistent enrichment of TP53 mutations in all four cancers. gATM mutations displayed elevated p53 transcriptional activity in all four cancers, with significance reached in breast and prostate cancers (P < 0.01). In breast, ovarian, and prostate cancers, gATM tumors demonstrated significantly increased inflammatory pathways (P < 0.001). Finally, using gene dependency data, we found that cell lines that were highly dependent on ATM were co-dependent on canonical p53 function. Conclusions: gATM-associated cancers seem to require intact p53 activity and this synthetic essentiality may be used to guide targeted therapies that perturb canonical TP53 function.
BR or R-CHOP induction with rituximab maintenance in untreated, transplant-ineligible patients with mantle cell lymphoma
Gutmair, Katja , Villa, Diego , Cunningham, Nicholas , Silkenstedt, Elisabeth , Rimsza, Lisa M. , Ramsower, Colleen , Scott, David W. , Dreyling, Martin , Hoster, Eva , Rimsza, Lisa, Gerrie, Alina S , Kluin-Nelemans, Hanneke C , Dreyling, Martin , Hoster, Eva , Scott, David W , Ramsower, Colleen A , Cunningham, Nicholas, Gerrie, Alina S. , Kluin‐Nelemans, Hanneke C.

Mayo Clinic

Blood Advances | February 21, 2025 | Volume: 9 | Issue: 9 | Pages: 2302-2306

10.1182/bloodadvances.2024015292 | PMID 39983085 Get It

Semaglutide and Nonarteritic Anterior Ischemic Optic Neuropathy
Cai, Cindy X. , Hribar, Michelle R. , Swaminathan, Swarup S. , Flowers, Alexis , Brown, Eric N. , Chen, John J. , Chen, Aiyin , Wang, Sophia Y. , Ehrlich, Joshua R. , Armbrust, Karen R. , Alshammari, Thamir , Swerdel, Joel N. , Suchard, Marc A. , Falconer, Thomas , DuVall, Scott L. , Viernes, Benjamin , O’Brien, William J. , Martin, Benjamin , Westlund, Erik , Mathioudakis, Nestoras , Fan, Ruochong, Stocking, Jacqueline C. , Takkouche, Sahar , Humes, Izabelle, McCoy, David , Adibuzzaman, Mohammad, Areaux, Raymond G. , Rojas‐Carabali, William , Brash, James T., Lee, David A. , Mawn, Louise A. , Agrawal, Rupesh, Morgan‐Cooper, Hannah, Desai, Priya , Ryan, Patrick , Barkmeier, Andrew, Chen, John J , Mathioudakis, Nestoras N , Stocking, Jacqueline C , Lee, Cecilia S , Baxter, Sally L. , Goetz, Kerry , Toy, Brian C. , Xu, Benjamin Yixing , Leng, Theodore , Barkmeier, Andrew J. , Boland, Michael V. , Dorr, David A , Boyce, Danielle M. , Schuemie, Martijn J. , Bu, Fan , Sena, Anthony G. , Hripcsak, George , Nishimura, Akihiko, Nagy, Paul G. , Matheny, Michael E. , Zhang, Linying , Martin, Benjamin, Fan, Ruochong, Wilcox, Adam B , Lai, Albert M. , Lee, Lok Hin , Xie, Yangyiran , Weiskopf, Nicole G. , Desai, Priya

Mayo Clinic

JAMA Ophthalmology | February 20, 2025 | Volume: 143 | Issue: 4 | Pages: 304

10.1001/jamaophthalmol.2024.6555 | PMID 39976940 Get It

Importance Semaglutide, a glucagonlike peptide-1 receptor agonist (GLP-1RA), has recently been implicated in cases of nonarteritic anterior ischemic optic neuropathy (NAION), raising safety concerns in the treatment of type 2 diabetes (T2D). Objective To investigate the potential association between semaglutide and NAION in the Observational Health Data Sciences and Informatics (OHDSI) network. Design, Setting, and Participants This was a retrospective study across 14 databases (6 administrative claims and 8 electronic health records). Included were adults with T2D taking semaglutide, other GLP-1RA (dulaglutide, exenatide), or non–GLP-1RA medications (empagliflozin, sitagliptin, glipizide) from December 1, 2017, to December 31, 2023. The incidence proportion and rate of NAION were calculated. Association between semaglutide and NAION was assessed using 2 approaches: an active-comparator cohort design comparing new users of semaglutide with those taking other GLP-1RAs and non–GLP-1RA drugs, and a self-controlled case-series (SCCS) analysis to compare individuals’ risks during exposure and nonexposure periods for each drug. The cohort design used propensity score–adjusted Cox proportional hazards models to estimate hazard ratios (HRs). The SCCS used conditional Poisson regression models to estimate incidence rate ratios (IRRs). Network-wide HR and IRR estimates were generated using a random-effects meta-analysis model. Exposures GLP-1RA and non–GLP-1RAs. Main Outcomes and Measures NAION under 2 alternative definitions based on diagnosis codes: one more inclusive and sensitive, the other more restrictive and specific. Results The study included 37.1 million individuals with T2D, including 810 390 new semaglutide users. Of the 43 620 new users of semaglutide in the Optum’s deidentified Clinformatics Data Mart Database, 24 473 (56%) were aged 50 to 69 years, and 26 699 (61%) were female. The incidence rate of NAION was 14.5 per 100 000 person-years among semaglutide users. The HR for NAION among new users of semaglutide was not different compared with that of the non–GLP-1RAs using the sensitive NAION definition—empagliflozin (HR, 1.44; 95% CI, 0.78-2.68; P = .12), sitagliptin (HR, 1.30; 95% CI, 0.56-3.01; P = .27), and glipizide (HR, 1.23; 95% CI, 0.66-2.28; P = .25). The risk was higher only compared with patients taking empagliflozin (HR, 2.27; 95% CI, 1.16-4.46; P = .02) using the specific definition. SCCS analysis of semaglutide exposure showed an increased risk of NAION (meta-analysis IRR, 1.32; 95% CI, 1.14-1.54; P < .001). Conclusions and Relevance Results of this study suggest a modest increase in the risk of NAION among individuals with T2D associated with semaglutide use, smaller than that previously reported, and warranting further investigation into the clinical implications of this association.
Dissociable spatial topography of cortical atrophy in early‐onset and late‐onset Alzheimer's disease: A head‐to‐head comparison of the LEADS and ADNI cohorts
Katsumi, Yuta , Touroutoglou, Alexandra , Brickhouse, Michael , Eloyan, Ani , Eckbo, Ryan, Zaitsev, Alexander, Joie, Renaud La , Thangarajah, Maryanne, Taurone, Alexander, Jack, Clifford R. , Dage, Jeffrey L. , Hammers, Dustin B. , Newell, Kathy L. , Polsinelli, Angelina J. , Aisen, Paul, Reman, Rema, Kramer, Joel H. , Day, Gregory S. , Duara, Ranjan , Graff‐Radford, Neill R. , Grant, Ian , Masdeu, Joseph C. , Mendez, Mario F. , Onyike, Chiadi U. , Riddle, Meghan , Rogalskı, Emily , Salloway, Stephen , Sha, Sharon, Turner, Raymond Scott , Wingo, Thomas S. , Carrillo, María C. , Rabinovici, Gil D. , Apostolova, Liana G. , Jack, Clifford R , Day, Gregory S , La Joie, Renaud , Rabinovici, Gil D , Wingo, Thomas S , Dage, Jeffrey L , Lagarde, Julien , Schonhaut, Daniel R. , Vemuri, Prashanthi , Nudelman, Kelly , Foroud, Tatiana , Hammers, Dustin B , Ghetti, Bernardino , Murray, Melissa E. , Beckett, Laurel , Atri, Alireza , Duara, Ranjan , Honig, Lawrence S. , Johnson, Erik C. B. , Jones, David T. , Masdeu, Joseph C , Musiek, Erik , Sha, Sharon J. , Wolk, David A. , Womack, Kyle , Dickerson, Bradford Clark

Mayo Clinic

Alzheimer's & Dementia | February 19, 2025 | Volume: 21 | Issue: 2 | Pages: No page available

10.1002/alz.14489 | PMID 39968692 Get It

Abstract INTRODUCTION Early‐onset and late‐onset Alzheimer's disease (EOAD and LOAD, respectively) have distinct clinical manifestations, with prior work based on small samples suggesting unique patterns of neurodegeneration. The current study performed a head‐to‐head comparison of cortical atrophy in EOAD and LOAD, using two large and well‐characterized cohorts (LEADS and ADNI). METHODS We analyzed brain structural magnetic resonance imaging (MRI) data acquired from 377 sporadic EOAD patients and 317 sporadicLOAD patients who were amyloid positive and had mild cognitive impairment (MCI) or mild dementia (i.e., early‐stage AD), along with cognitively unimpaired participants. RESULTS After controlling for the level of cognitive impairment, we found a double dissociation between AD clinical phenotype and localization/magnitude of atrophy, characterized by predominant neocortical involvement in EOAD and more focal anterior medial temporal involvement in LOAD. DISCUSSION Our findings point to the clinical utility of MRI‐based biomarkers of atrophy in differentiating between EOAD and LOAD, which may be useful for diagnosis, prognostication, and treatment. Highlights Early‐onset Alzheimer's disease (EOAD) and late‐onset AD (LOAD) patients showed distinct and overlapping cortical atrophy patterns. EOAD patients showed prominent atrophy in widespread neocortical regions. LOAD patients showed prominent atrophy in the anterior medial temporal lobe. Regional atrophy was correlated with the severity of global cognitive impairment. Results were comparable when the sample was stratified for mild cognitive impairment (MCI) and dementia.
Addressing the High and Rising Global Burden of Metabolic Dysfunction‐Associated Steatotic Liver Disease ( MASLD ) and Metabolic Dysfunction‐Associated Steatohepatitis ( MASH
Younossi, Zobair M. , Sherman, Michael S., Anstee, Quentin M. , Cusi, Kenneth , Lazarus, Jeffrey V. , Schuppan, Detlef, Schattenberg, Jörn M. , Vos, Miriam B. , Anstee, Quentin M , Cusi, Kenneth , Lazarus, Jeffrey V , Schuppan, Detlef , Romero-Gómez, Manuel , Wong, Vincent Wai-Sun , Sanyal, A J , Loomba, Rohit , Schattenberg, Jörn M , Razavi, Homie , Sherman, Michael, Allen, Alina M. , Friedman, Scott L. , Lawitz, Eric , Wong, Vincent Wai‐Sun , Ratziu, Vlad , Hompesch, Marcus , Sanyal, Arun J. , Loomba, Rohit

Mayo Clinic

Alimentary Pharmacology & Therapeutics | February 19, 2025 | Volume: 61 | Issue: 9 | Pages: 1467-1478

10.1111/apt.70020 | PMID 39967239 Get It

ABSTRACT Background The continuum of metabolic syndrome encompasses a spectrum of dysfunctions impacting obesity‐linked insulin resistance, glucose homeostasis, lipid metabolism and pro‐inflammatory immune responses. The global prevalence of metabolic diseases, including diabetes, chronic liver disease, cardiometabolic disease and kidney disease, has surged in recent decades, contributing significantly to population mortality. Metabolic dysfunction‐associated steatotic liver disease (MASLD), formerly known as non‐alcoholic fatty liver disease, is a leading cause of liver disease worldwide. MASLD poses a significant global health challenge with its rising prevalence, placing a substantial burden on healthcare systems, impacts patient well‐being and incurs significant economic costs. Addressing MASLD requires a comprehensive understanding of its interconnected factors, including its prevalence, healthcare burden and economic implications. Lack of awareness, imprecise non‐invasive diagnostic methods and ineffective preventive interventions are core components of the MASLD‐related problem. Aim The aim of this article was to summarise the global burden of MASLD from the payer's perspective. Methods We carried out a review of the global comprehensive burden of MASLD. These topics led to discussions and insights by an expert panel during the 7th Metabolic Continuum Roundtable meeting, which took place in November 2023. This meeting focused on the burden, patient‐reported outcomes and health economics, from payor and societal perspectives, and aimed to identify opportunities for improving patient care, optimise resource allocation and mitigate the overall impact on individuals and society related to MASLD. During the roundtable, an emphasis emerged on the need for greater awareness and strategic deployment of diagnostic, therapeutic and preventative measures to address MASLD effectively. Conclusion The global burden of MASLD is high and growing. Prioritising the prevention of metabolic dysregulation and timely therapeutic interventions can yield a holistic strategy to combat MASLD, its progression and potentially lower disease costs. Trial Registration: NCT06309992
ProstACT GLOBAL: A phase 3 study of 177 Lu-rosopatamab (TLX591) with and without the best standard of care for patients with PSMA expressing metastatic castration-resistant prostate cancer progressing despite prior treatm
Sartor, Alton Oliver, Cade, David, Agarwal, Neeraj , Tagawa, Scott T. , Lenzo, Nat P. , Agarwal, Neeraj

Mayo Clinic

Journal of Clinical Oncology | February 18, 2025 | Volume: 43 | Issue: 5_suppl | Pages: No page available

10.1200/jco.2025.43.5_suppl.tps303 Get It

TPS303 Background: The treatment of advanced prostate cancer (PC) is challenging, with undesirable side effects that impact patient quality of life. Radioimmunotherapy (RIT) can localize therapy to specific tumor cells in multiple organs to reduce or eliminate damage to normal tissue. The cell surface glycoprotein prostate-specific membrane antigen (PSMA) is an ideal therapeutic target as it is highly expressed by malignant prostate cells. There is a strong rationale for further investigation of the 177 Lu-labeled, chelator-conjugated antibody, 1 77 Lu-rosopatamab, as a potential first-line RIT candidate for the treatment of PC. Methods: This multinational, multicenter, prospective, randomized, open label phase 3 study will have 2 parts: a dosimetry and safety lead-in (n=30) and a randomized treatment expansion (n=490). In Part 1, patients will be divided into 3 groups (n=10 each) to receive 2 single intravenous (IV) injections of 76 millicuries (mCi) each, 14 days apart, of 177 Lu-rosopatamab with best standard of care (SoC) combinations with abiraterone, enzalutamide, or docetaxel to fully characterize biodistribution and safety profiles of 177 Lu-DOTA-rosopatamab + SoC combinations. SoC received will be determined prior to treatment with 177 Lu-rosopatamab. In Part 2, patients will be enrolled in a 2:1 ratio to receive either the best SoC or 2 single IV injections of 76 mCi each (equivalent to a 45 mCi/m 2 dose in a standard 1.7m 2 individual) of 177 Lu-rosopatamab, given 14 days apart, plus best SoC. SoC will be determined prior to randomization, and a change in planned SoC will not be permitted. Eligible patients must have PSMA-expressing metastatic castration-resistant PC (mCRPC) that have progressed despite prior therapy with either enzalutamide or abiraterone plus prednisone, and 1 line of prior taxane therapy or have refused or are ineligible for taxanes. Patients must have adequate organ function including at least 150x10 9 /L platelets, hemoglobin 10 g/dL, and have PSMA-positive disease on 68 Ga-PSMA-11 PET/CT imaging as confirmed by a central reader. Key exclusion criteria include small cell histology, increased risk of hemorrhage or bleeding, known brain or hepatic metastases, or history of stroke, seizure, or treatment with radioisotopes within 6 months prior to randomization. The primary endpoint is radiographic progression-free survival. Key secondary endpoint is OS. Additional secondary endpoints include 5-year overall survival, tumor objective response rate, time to symptomatic skeletal event, and health-related quality of life. Clinical trial information: NCT04876651 .
Efficacy of 177 Lu-PSMA-617 with or without ARPIs for the treatment of mCRPC: VISION secondary analysis.
Yazdanpanah, Omid , Calais, Jérémie , Bono, Johann S. de , Deymann, Sheila, El‐Haddad, Ghassan , Herrmann, Ken, Fizazi, Karim , González, Daniel Gallego , Kendi, Ayşe Tuba Karagülle, Krause, Bernd J. , Nordquist, Luke T., Sartor, Alton Oliver, Vaishampayan, Nitin, Rezazadeh, Arash, Calais, Jeremie , de Bono, Johann , N., Kim , Gonzalez, Diego Ospina, Morris, Michael J. , Nagarajah, James , Rahbar, Kambiz , Tagawa, Scott T. , Yue, Ye

Mayo Clinic

Journal of Clinical Oncology | February 18, 2025 | Volume: 43 | Issue: 5_suppl | Pages: 121-121

10.1200/jco.2025.43.5_suppl.121 Get It

121 Background: In the Phase 3 VISION trial, treatment with the prostate-specific membrane antigen (PSMA)-targeted radioligand therapy [ 177 Lu]Lu-PSMA-617 ( 177 Lu-PSMA-617) + protocol-permitted standard of care (SoC) significantly improved median radiographic progression-free survival (rPFS; 8.7 vs 3.4 months [mo]) and overall survival (OS; 15.3 vs 11.3 mo) in patients with metastatic castration-resistant prostate cancer (mCRPC) vs SoC alone. However, it is unclear how the addition of androgen receptor pathway inhibitors (ARPIs) affected 177 Lu-PSMA-617 treatment outcomes. Here we compared the efficacy and safety of 177 Lu-PSMA-617 in patients treated with vs without concomitant ARPIs. Methods: In VISION, adult patients with PSMA-positive mCRPC previously treated with ≥1 prior ARPI and 1–2 taxane chemotherapy regimens were randomized 2:1 to receive 177 Lu-PSMA-617 (7.4 GBq Q6W, 4–6 cycles) + SoC (which included ARPIs) vs SoC alone. In this secondary analysis, we assessed baseline characteristics, OS, rPFS, prostate-specific antigen (PSA) response rate, duration of PSA response, PSA-PFS, and safety among patients in the intervention arm who were treated with vs without concomitant ARPIs. Results: In total, 289 patients were treated with concomitant ARPIs and 262 patients were not (N=551). Imbalances between the groups were observed in some baseline characteristics: patients treated with concomitant ARPIs were younger, had lower ECOG performance scores, lower mean PSA and lactate dehydrogenase levels, and fewer prior taxane chemotherapy regimens. Baseline mean standardized [ 68 Ga]Ga-PSMA-11 uptake values and mean hemoglobin levels were well-balanced. A statistically significant difference in median OS was observed in patients treated with concomitant ARPIs vs those without (17.8 vs 12.4 mo; HR, 0.72; 95% CI, 0.58–0.89; nominal P=0.001). No statistically significant between-group differences were observed for rPFS, PSA response rate, duration of PSA response or PSA-PFS. The proportion of adverse events reported was similar in patients with or without concurrent ARPI, except for the number of adverse events leading to interruption of best supportive care/SoC, which was higher in patients treated with concurrent ARPIs. Conclusions: OS was significantly different in patients treated with concomitant ARPIs vs those without, while other efficacy endpoints were not. No new safety signals were observed for 177 Lu-PSMA-617 with concomitant ARPI. These findings may be confounded by varied exposure to ARPIs, or differing patient characteristics; patients who received concomitant ARPIs may represent a more favorable treatment population than those who did not. These findings should be considered as hypothesis-generating, and a multivariate analysis has been planned to ascertain the influence of these potential biases. Clinical trial information: NCT03511664 .